Loading…
Employees: 656
Size SD Biosensor (137310.KS) is a South Korea Health Care company (Electronic Equipment/Instruments) with a market value of $573M, the 312th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩6,560 on 6 Nov 2026.
Performance Over six months the shares fell 22.1%, against -28.1% for the median peer and -24.5% for the South Korea market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue grew 5.2% over the last twelve months (peer median +9.6%); the operating margin is -8.9% (peer median 6.7%).
Valuation It trades at 0.9× enterprise value to sales against a peer median of 1.8× (7th cheapest of 21).
Price implies For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is -16%, so the hurdle is +34 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 7.3 points below its cost of capital (5.2% WACC).
Next results Next results expected around 16 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩739B | ₩711B | ₩695B | ₩656B | ₩2.93T |
| Revenue growth | — | +2% | +6% | -78% | — |
| Gross profit | ₩252B | ₩224B | ₩241B | ₩29.2B | ₩1.38T |
| EBITDA | ₩59.9B | ₩51.4B | ₩87.2B | -₩111B | ₩1.19T |
| Net income | -₩729B | -₩512B | -₩98.4B | -₩468B | ₩911B |
| Free cash flow | ₩11.1B | ₩300B | ₩77.7B | -₩385B | ₩593B |
| Capital expenditure | ₩46.0B | ₩57.5B | ₩80.9B | ₩145B | ₩300B |
| Total debt | ₩285B | ₩669B | ₩607B | ₩604B | ₩24.8B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Sector in the same market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 137310.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.2% | -12.9% | 7th highest of 21 |
| 6-month return | -22.1% | -28.1% | 8th highest of 21 |
| Distance from 52-week high | -34.0% | -47.7% | 6th highest of 21 |
| Revenue growth (TTM) | +5.2% | +9.6% | 6th lowest of 21 |
| Operating margin | -8.9% | 6.7% | 7th lowest of 21 |
| EV / Sales | 0.9× | 1.8× | 7th cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | 17.9% | -8.9% | most demanding of 10 |
| Growth delivered (Del g) | -15.9% | +12.6% | lowest of 10 |
| Hurdle (Req g minus delivered) | +33.8 pp | -23.6 pp | most demanding of 10 |
| ROIC minus cost of capital | -7.3 pp | +0.9 pp | 6th lowest of 20 |
| EV / EBITDA | 11.0× | 7.7× | 4th most expensive of 10 |
| Net debt / EBITDA | -2.0× | 0.5× | 3rd least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| SD Biosensor 137310.KS | South Korea | $573M | -22% | +5% | -9% | 0.9× | 17.9% | -15.9% |
| Chongkundang 185750.KS | South Korea | $611M | -26% | +7% | 4% | 0.5× | n/a | n/a |
| Boryung 003850.KS | South Korea | $531M | -14% | +6% | 6% | 0.7× | -8.9% | +12.6% |
| Qurient 115180.KS | South Korea | $503M | -59% | -20% | -517% | 98.9× | n/a | n/a |
| Daewoong 003090.KS | South Korea | $485M | -29% | +5% | 11% | 0.9× | n/a | n/a |
| JS Link 127120.KS | South Korea | $481M | -57% | +51% | -76% | 28.2× | n/a | n/a |
| Livsmed 491000.KS | South Korea | $706M | -47% | +89% | -59% | 17.2× | n/a | n/a |
| Komipharm International 041960.KS | South Korea | $460M | -12% | -3% | 2% | 12.1× | n/a | n/a |
| Myung in Pharm 317450.KS | South Korea | $455M | -24% | +7% | 35% | 2.1× | -14.7% | +8.9% |
| PROTEINA 468530.KS | South Korea | $450M | -2% | -59% | -1,178% | 410.3× | n/a | n/a |
| HK inno.N 195940.KS | South Korea | $745M | -32% | +7% | 12% | 0.9× | -10.8% | +12.2% |
| Dong-A Socio 000640.KS | South Korea | $425M | -11% | +10% | 7% | 0.7× | -8.8% | +12.8% |
| DongKook Pharmaceutical 086450.KS | South Korea | $776M | -1% | +13% | 10% | 1.1× | -6.3% | +10.6% |
| SEERS 458870.KS | South Korea | $409M | -70% | +425% | 43% | 5.5× | -9.1% | +247.0% |
| SK Discovery 006120.KS | South Korea | $804M | +11% | +20% | 3% | 0.8× | n/a | n/a |
| JW Pharmaceutical 001060.KS | South Korea | $402M | -28% | +10% | 14% | 0.7× | -16.9% | +7.2% |
| Hyundai Bioscience 048410.KS | South Korea | $401M | -58% | +78% | -580% | 158.2× | n/a | n/a |
| Onconic Therapeutics 476060.KS | South Korea | $391M | -45% | +179% | 21% | 5.7× | 2.0% | +725.2% |
| Rznomics 476830.KS | South Korea | $386M | -79% | -72% | -1,440% | 244.5× | n/a | n/a |
| InBody 041830.KS | South Korea | $378M | +43% | +21% | 19% | 1.4× | -7.6% | +16.9% |
| Daewoong Pharm 069620.KS | South Korea | $874M | -30% | +9% | 12% | 0.7× | n/a | n/a |